+ Watch OCLS
on My Watchlist
The Company has developed and it manufactures and markets, a family of products intended to prevent and treat infections in chronic and acute wounds.
For once I got lucky in CAPS, exiting the pick with a healthy positive score after the company predictably reported flat revenues last week.Lo and behold, the share price is shooting up today close to one-year highs after the company blared "New FDA 510(k) Clearance for Microcyn-Based Dermatology HydroGel for Management of Atopic Dermatitis, Radiation Dermatitis and Other Skin Dermatoses"!Wow, that sounds official. Maybe I've been wrong about the commercial potential of diluted bleach for wound care. But something gnawed at me, a strange sense of deja vu. Then I reviewed my biotech database and found that the stock jumped in a very similar way last March on what appeared to be very similar news.Strangely, that press release (along with all other press releases between September 2008 and September 2010) is missing from the Oculus website. But I did manage to find it archived on other websites with a Google search. Seems like Oculus already received an FDA clearance to market Microcyn Hydrogel for wounds and skin irritations a year ago, and they launched it at about the same time. The result? Flat revenues.Of course, the company touts year-over-year revenue increases in their recent quarterly PR. But in the fast-moving world of drugs we like to look at quarterly trends, especially with a newly-launched product. And the story since Hydrogel marketing began a year ago is flat revenues.So now Hydrogel is approved AGAIN! Quick, jump on the train before it leaves the station! But I'm looking back at the chart, and seeing a 50% drop in share price in the six months after the FDA cleared Hydrogel the first time.
I made money today!!!!!! A lot!!!! You sound familiar, too, like a sore looser. Good luck.
You have to sell the stock to make money. I don't think you'll be out of the trailer any time soon.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions